Related Experiment Video
Updated: Jan 26, 2026

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making
Published on: March 2, 2011
Clinical and economic aspects of newborn screening for severe combined immunodeficiency: DEPISTREC study results
Caroline Thomas1, Isabelle Durand-Zaleski2, Jérôme Frenkiel2
1Service d'oncologie-hématologie et immunologie pédiatrique, CHU Nantes, Nantes, France.
Insights
Newborn screening for Severe Combined Immunodeficiency (SCID) using T-cell receptor excision circles (TRECs) is feasible and effective. This method aids in early diagnosis and treatment, potentially preventing infant mortality from SCID.
Area of Science:
- Immunology
- Genetics
- Pediatrics
Background:
- Severe Combined Immunodeficiency (SCID) comprises genetic disorders severely impairing cellular and humoral immunity.
- Infants with SCID are vulnerable to fatal infections within months if untreated.
- Quantification of T-cell receptor excision circles (TRECs) is a sensitive screening method for SCID.
Purpose of the Study:
- To evaluate the feasibility, economic, and clinical utility of nationwide newborn screening for SCID in France.
- To assess the effectiveness of TREC quantification for detecting severe T-cell lymphopenia.
Main Methods:
- A nationwide newborn screening program for SCID was implemented, analyzing TRECs on Guthrie cards.
- The study compared 190,517 screened infants with a control group of 1.4 million infants diagnosed without screening.
- Data on lymphopenia, SCID diagnoses, and costs were collected and analyzed.
Main Results:
- The screening identified 62 lymphopenic infants, including three with SCID.
- The cost per newborn screening ranged from €4.7 to €8.15.
- The average 18-month cost for screened infants was higher than for the control group, though the difference was not fully ascertainable.
Conclusions:
- Routine newborn screening for SCID is demonstrated to be feasible and effective in a large-scale study.
- SCID screening aids in diagnosing non-SCID lymphopenia and can prevent SCID-related deaths before treatment.
- Economic evaluation provides cost-per-test data for implementing nationwide screening programs.
Purpose:
Severe combined immunodeficiency (SCID) refers to a group of genetic disorders characterized by greatly compromised cellular and humoral immunity. Children with SCID are asymptomatic at birth, but they die from infections within the first months of life if not treated. Quantification of T-cell receptor excision circles is an extremely sensitive screening method for detecting newborns who may have SCID.The goal of the DEPISTREC study was to evaluate the feasibility of nationwide newborn screening for severe T-cell lymphopenia in France as well as its economic and clinical utility.
Methods:
The test universally used for neonatal screening for SCID was the quantification of TRECs on Guthrie cards. We compared a group of 190,517 babies from 48 maternities across the country who underwent newborn SCID screening with a control group of 1.4 million babies out of whom 28 were diagnosed with SCID without such screening during the course of the study.
Results:
Within the screening group, 62 babies were found to be lymphopenic, including three with SCID. The cost of screening ranged from 4.7€ to €8.15 per newborn. The average 18-month cost was €257,574 vs €204,697 in the control group.
Conclusions:
In this large-scale study, we demonstrate that routine SCID screening is feasible and effective. This screening offers the additional benefit of aiding in the diagnosis of non-SCID lymphopenia. Economic evaluation allowed us to calculate the cost per test. Newborn screening may also prevent death by SCID before any curative treatment can be administered. The difference in cost between screened and control children could not be ascertained because of the very low numbers and death of one of the children tested.
Related Concept Videos
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Hypertension III: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Quantitative Aspects of Drug-Receptor Interaction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

